Progesterone Injection is a prescription medication used to provide hormone support for individuals with low or imbalanced progesterone levels. Progesterone is a naturally occurring hormone that plays a crucial role in regulating menstrual cycles, supporting pregnancy, and maintaining reproductive health. The injectable form allows for precise dosing and faster absorption, making it an effective option for medical conditions such as luteal phase defects, infertility treatment, or hormonal replacement therapy. It is administered under professional care to ensure safety and appropriate monitoring.

Progesterone Injection works by supplementing the body’s natural hormone levels and binding to specific progesterone receptors throughout the reproductive system and other tissues. It helps regulate the menstrual cycle by preparing the uterine lining for embryo implantation and supporting early pregnancy by maintaining a stable hormonal environment. The injection also balances the effects of estrogen, reducing symptoms associated with hormonal fluctuations such as mood disturbances, hot flashes, and irregular bleeding. By providing direct and fast-acting hormone support, it helps restore physiological balance and improve reproductive health.

Progesterone Injection should not be used by individuals who have allergies to progesterone or any of its components. It is also contraindicated in women with certain cancers sensitive to hormones, unexplained vaginal bleeding, liver disease, or a history of blood clots. Before using the injection, it is essential to inform your healthcare provider about any medications, supplements, or medical conditions you are managing to avoid potential interactions. Regular monitoring of blood pressure, liver function, and hormone levels may be recommended to ensure safety. The injection must be administered by a healthcare professional, and self-administration is strongly discouraged.

Potential interactions include: barbiturate; drugs for sleep or seizure; bexarotene; carbamazepine; ethotoin; ketoconazole; phenytoin; rifampin This list might not cover every potential interaction. List all the medications, herbs, over-the-counter pharmaceuticals, or nutritional supplements you consume for your health care professional. Let them know as well whether you drink, smoke, or use prohibited substances. Certain goods might react with your medication.

Drugs capable of producing hepatic enzymes can hasten the breakdown of hormones including hormone contraceptives.

Drugs that can induce hepatic enzymes can accelerate the rate of metabolism of hormones including hormonal contraceptives. In patients taking phenytoin—the active metabolite of fosphenytoin—undergoing treatment with estrogens, oral contraceptives, or progestins, pregnancy has been noted.[11][10] Women on both hormones and liver enzyme-inducing medications should let their doctors know about breakthrough bleeding. Patients recommended simultaneous treatment with enzyme-inducing anticonvulsants or higher-dose hormone regimens may be appropriate or useful. After stopping the interacting medicine, the alternate or additional contraceptive agent might need to be carried for one month. While taking fosphenytoin, patients receiving these hormones for other reasons should be monitored for decreased clinical impact and dose changes should be determined depending on clinical efficacy.

While many users benefit from Progesterone Injection, some may experience side effects during or after treatment. Common reactions include injection site discomfort, swelling, or mild pain, as well as headaches, dizziness, or nausea. Hormonal changes may also lead to mood swings, breast tenderness, or temporary weight gain. Rare but serious side effects, such as allergic reactions, severe swelling, or unusual bleeding, require immediate medical attention. Following the prescribed dosage and monitoring guidelines helps reduce the risk of side effects and ensures that the treatment remains effective and safe.

Progesterone is essential during pregnancy, and in some cases, Progesterone Injection is prescribed to support early pregnancy or manage conditions that affect reproductive health. However, it should only be used when recommended by a healthcare provider, as improper dosing could interfere with pregnancy. During breastfeeding, progesterone may pass into breast milk, so consultation with a healthcare provider is necessary before starting treatment. The doctor will assess the benefits and potential risks to both the mother and the infant to ensure that the medication is used safely and appropriately.

Store this medication at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.

1. Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Eng J Med 2003;348:2379-85.
2. ACOG Committee on Obstetric Practice. Committee Opinion: use of progesterone to reduce preterm birth. Obstet Gynecol 2003;102:1115-6.
3. Fonseca EB, Celik E, Parra M, et al. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007;357:462-8.
4. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
5. Endometrin (progesterone) vaginal insert package insert. Hunt Valley, MD: Pharmaceutics International, Inc.; 2014 Jun.
6. Crinone (progesterone vaginal gel) package insert. Parsippany, NJ: Watson Pharma, Inc.; 2011 Dec.
7. American Academy of Pediatrics (AAP) Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776-89.
8. Prometrium® (progesterone) package insert. Marietta, GA: Solvay Pharmaceuticals Inc.; 1998 Dec.
9. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women’s Health Initiative Memory Study: A randomized controlled trial (WHIMS). JAMA 2003;289:2651-62.
10. Dilantin® Kapseals® (extended phenyotin sodium capsules, USP) package insert. Morris Plains, NJ: Parke Davis; 1999 Aug.
11. Cerebyx® (fosphenytoin sodium) package insert. New York, NY: Parke-Davis; 2002 Jun.
12. Peganone® (ethotoin) package insert. Deerfield, IL: Ovation Pharmaceuticals, Inc.; 2003 Sep.
13. Tegretol® (carbamazepine) package insert. East Hanover, NJ. Novartis Pharmaceuticals; 2003 Sept.
14. Carbatrol® (carbamazepine) package insert. Wayne, PA. Shire US Inc; 2006 Jul.
15. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs. 2002;16:263—72.
16. Berman ML, Green OC. Acute stimulation of cortisol metabolism by pentobarbital in man. Anesthesiology 1971;34:365—9.
17. Phenobarbital Tablets, USP package insert. Elizabeth, NJ: Purepac Pharmaceuticals; 2000 Oct.[/fnElestrin™ (estradiol) package insert. San Antonio,TX: DPT Laboratories, Ltd.; 2006 Dec.
18. Endometrin® (progesterone) package insert. Hunt Valley, MD: Pharmaceutics International, Inc.; 2007 Jun.
19. Lewis DP, VanDyke DC, Stumbo PJ, et al. Drug and environmental factors associated with adverse pregnancy outcomes Part 1: Antiepileptic drugs, contraceptives, smoking and folate. Ann Pharmacother 1998;32:802—17.
20. Hansten P, Horn J. The Top 100 Drug Interactions: A Guide to Patient Management. includes table of CYP450 and drug transporter substrates and modifiers (appendices). H & H Publications, LLP 2014 edition.
21. Kyriazopoulou V, Parparousi O, Vagenakis A. Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. J Clin Endocrinol Metab 1984;59:1204—6.
22. Elestrin™ (estradiol) package insert. San Antonio,TX: DPT Laboratories, Ltd.; 2006 Dec.
23. Archer JSM, Archer DF. Oral contraceptive efficacy and antibiotic interaction: A myth debunked. J Am Acad Dermatol 2002;46:917—23.
24. Dickinson BD, Altman RD, Nielsen NH, Sterling ML, for the Council on Scientific Affairs, American Medical Association (AMA). Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 2001;98:853—60. Review.
25. VFEND® (voriconazole) package insert. New York,NY: Pfizer Inc; 2008 Mar.
26. Uniphyl® (theophylline, anhydrous) tablets package insert. Stamford, CT: Purdue Pharmaceutical Products LP; 2004 Mar.
27. Biaxin® (clarithromycin) package insert. North Chicago, IL: Abbott Laboratories; 2007 March.
28. Cardizem® CD (diltiazem) package insert. Kansas City, MO: Aventis Pharmaceuticals, Inc.; 2007 Sep.
29. Emend® capsules (aprepitant) package insert. Whitehouse Station, NJ: Merck & Co., Inc.; 2007 Nov.
30. Parlodel (bromocriptine) package insert. East Hanover, NJ: Novartis Pharmaceutical Corporation, Inc.; 2003 Mar.
31. Christen RD, McClay EF, Plaxe SC, et al. Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin. J Clin Oncol 1993;11:2417—26.
32. Targretin® (bexarotene capsules) package insert. San Diego CA: Ligand Pharmaceuticals Inc.; 2003 April.
33. Tracleer® (bosentan) package insert. South San Francisco, CA: Actelion Pharmaceuticals US, Inc.; 2007 Feb.
34. Saha GB. Fundamentals of nuclear pharmacy. 3rd ed. New York: Springer-Verlag New York, Inc.; 1992.
35. Progesterone capsule package insert. High Point, NC: Banner Pharmacaps Inc; 2013 Nov.
36. Prochieve (progesterone) vaginal gel package insert. Livingston, NJ: Columbia Laboratories, Inc.; 2009 Nov.
37. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93.
38. World Health Organization. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-8.
39. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-6.